Do analysts rate GNTA or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, GNTA or ASBP?

Genenta Science has higher earnings, but lower revenue than Aspire Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Aspire Biopharma $10K 947.05 -$24.48M -$116.67 N/A

Is GNTA or ASBP more profitable?

Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A Aspire Biopharma N/A N/A -398.04%

Do analysts rate MIRA or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MIRA or ASBP more profitable?

Aspire Biopharma's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% Aspire Biopharma N/A N/A -398.04%

Does the media refer more to MIRA or ASBP?

In the previous week, Aspire Biopharma had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Aspire Biopharma and 1 mentions for MIRA Pharmaceuticals. Aspire Biopharma's average media sentiment score of 0.56 beat MIRA Pharmaceuticals' score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aspire Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ASBP or SCYX?

SCYNEXIS has a consensus price target of $24.00, indicating a potential upside of 340.77%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media favor ASBP or SCYX?

In the previous week, SCYNEXIS had 2 more articles in the media than Aspire Biopharma. MarketBeat recorded 4 mentions for SCYNEXIS and 2 mentions for Aspire Biopharma. Aspire Biopharma's average media sentiment score of 0.56 beat SCYNEXIS's score of 0.25 indicating that Aspire Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ASBP or CRVO?

CervoMed has a consensus price target of $21.50, suggesting a potential upside of 676.73%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CervoMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Is ASBP or CRVO more profitable?

Aspire Biopharma has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Aspire Biopharma's return on equity of 0.00% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% CervoMed -672.80% -136.08% -112.62%

Does the media favor ASBP or CRVO?

In the previous week, CervoMed had 2 more articles in the media than Aspire Biopharma. MarketBeat recorded 4 mentions for CervoMed and 2 mentions for Aspire Biopharma. CervoMed's average media sentiment score of 1.00 beat Aspire Biopharma's score of 0.56 indicating that CervoMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CervoMed 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ASBP or ADXS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ASBP or ADXS more profitable?

Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% Ayala Pharmaceuticals N/A N/A N/A

Does the media favor ASBP or ADXS?

In the previous week, Aspire Biopharma had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Aspire Biopharma and 1 mentions for Ayala Pharmaceuticals. Aspire Biopharma's average media sentiment score of 0.56 beat Ayala Pharmaceuticals' score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aspire Biopharma (ASBP) Competitors

$6.89 -0.15 (-2.13%)

As of 09:47 AM Eastern

Compare

ASBP vs. GNTA, MIRA, SCYX, CRVO, and ADXS

Should you buy Aspire Biopharma stock or one of its competitors? MarketBeat compares Aspire Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aspire Biopharma include Genenta Science (GNTA), MIRA Pharmaceuticals (MIRA), SCYNEXIS (SCYX), CervoMed (CRVO), and Ayala Pharmaceuticals (ADXS).

How does Aspire Biopharma compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Aspire Biopharma	N/A	N/A	-398.04%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aspire Biopharma had 2 more articles in the media than Genenta Science. MarketBeat recorded 2 mentions for Aspire Biopharma and 0 mentions for Genenta Science. Aspire Biopharma's average media sentiment score of 0.56 beat Genenta Science's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Genenta Science	Neutral
Aspire Biopharma	Positive

Genenta Science has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market.

Genenta Science has higher earnings, but lower revenue than Aspire Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Aspire Biopharma	$10K	947.05	-$24.48M	-$116.67	N/A

Summary

Genenta Science and Aspire Biopharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Aspire Biopharma compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

MIRA Pharmaceuticals has higher earnings, but lower revenue than Aspire Biopharma. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Aspire Biopharma	$10K	947.05	-$24.48M	-$116.67	N/A

Aspire Biopharma's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Aspire Biopharma	N/A	N/A	-398.04%

MIRA Pharmaceuticals has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market.

In the previous week, Aspire Biopharma had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Aspire Biopharma and 1 mentions for MIRA Pharmaceuticals. Aspire Biopharma's average media sentiment score of 0.56 beat MIRA Pharmaceuticals' score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MIRA Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aspire Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 19.9% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

MIRA Pharmaceuticals beats Aspire Biopharma on 8 of the 13 factors compared between the two stocks.

How does Aspire Biopharma compare to SCYNEXIS?

Aspire Biopharma (NASDAQ:ASBP) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Aspire Biopharma has a beta of 0.11, meaning that its share price is 89% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Aspire Biopharma has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Aspire Biopharma's return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
SCYNEXIS	-41.79%	-57.16%	-39.48%

In the previous week, SCYNEXIS had 2 more articles in the media than Aspire Biopharma. MarketBeat recorded 4 mentions for SCYNEXIS and 2 mentions for Aspire Biopharma. Aspire Biopharma's average media sentiment score of 0.56 beat SCYNEXIS's score of 0.25 indicating that Aspire Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SCYNEXIS has higher revenue and earnings than Aspire Biopharma. SCYNEXIS is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	947.05	-$24.48M	-$116.67	N/A
SCYNEXIS	$20.60M	2.62	-$8.61M	-$3.84	N/A

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 4.1% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SCYNEXIS has a consensus price target of $24.00, indicating a potential upside of 340.77%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

SCYNEXIS beats Aspire Biopharma on 10 of the 16 factors compared between the two stocks.

How does Aspire Biopharma compare to CervoMed?

Aspire Biopharma (NASDAQ:ASBP) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

CervoMed has a consensus price target of $21.50, suggesting a potential upside of 676.73%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Aspire Biopharma has a beta of 0.11, meaning that its share price is 89% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.63, meaning that its share price is 163% less volatile than the broader market.

In the previous week, CervoMed had 2 more articles in the media than Aspire Biopharma. MarketBeat recorded 4 mentions for CervoMed and 2 mentions for Aspire Biopharma. CervoMed's average media sentiment score of 1.00 beat Aspire Biopharma's score of 0.56 indicating that CervoMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CervoMed	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aspire Biopharma has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Aspire Biopharma's return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
CervoMed	-672.80%	-136.08%	-112.62%

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 35.8% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Aspire Biopharma has higher earnings, but lower revenue than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	947.05	-$24.48M	-$116.67	N/A
CervoMed	$4.01M	9.34	-$26.97M	-$3.28	N/A

Summary

CervoMed beats Aspire Biopharma on 10 of the 16 factors compared between the two stocks.

How does Aspire Biopharma compare to Ayala Pharmaceuticals?

Aspire Biopharma (NASDAQ:ASBP) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
Ayala Pharmaceuticals	N/A	N/A	N/A

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aspire Biopharma has higher earnings, but lower revenue than Ayala Pharmaceuticals. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	947.05	-$24.48M	-$116.67	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Aspire Biopharma has a beta of 0.11, meaning that its share price is 89% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

In the previous week, Aspire Biopharma had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Aspire Biopharma and 1 mentions for Ayala Pharmaceuticals. Aspire Biopharma's average media sentiment score of 0.56 beat Ayala Pharmaceuticals' score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aspire Biopharma beats Ayala Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get Aspire Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASBP vs. The Competition

Export

Metric	Aspire Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.47M	$11.51B	$6.84B	$12.77B
Dividend Yield	N/A	2.73%	2.60%	10.01%
P/E Ratio	-0.06	791.62	279.15	25.53
Price / Sales	947.05	735.80	590.96	92.31
Price / Cash	N/A	71.54	72.11	49.39
Price / Book	-0.13	10.85	13.02	6.11
Net Income	-$24.48M	$2.81B	$3.48B	$347.58M
7 Day Performance	29.86%	2.73%	3.40%	4.91%
1 Month Performance	17.31%	-3.09%	-2.80%	-2.06%
1 Year Performance	-98.28%	191.01%	73.17%	21.03%

Aspire Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASBP Aspire Biopharma	0.1755 of 5 stars	$6.89 -2.1%	N/A	-98.4%	$8.96M	$10K	N/A	N/A	News Coverage Gap Up
GNTA Genenta Science	0.6094 of 5 stars	$1.59 -3.6%	N/A	-66.3%	$37.51M	N/A	N/A	7
MIRA MIRA Pharmaceuticals	0.2527 of 5 stars	$0.88 -5.0%	N/A	-57.0%	$37.06M	N/A	N/A	2	Gap Up
SCYX SCYNEXIS	3.7173 of 5 stars	$3.73 -5.8%	$24.00 +543.4%	-3.0%	$37.04M	$20.34M	N/A	60	News Coverage Upcoming Earnings
CRVO CervoMed	3.4182 of 5 stars	$2.66 -0.4%	$22.60 +749.6%	-70.0%	$35.98M	$4.01M	N/A	4	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASBP) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aspire Biopharma (ASBP) Competitors

ASBP vs. GNTA, MIRA, SCYX, CRVO, and ADXS

How does Aspire Biopharma compare to Genenta Science?

Summary

How does Aspire Biopharma compare to MIRA Pharmaceuticals?

Summary

How does Aspire Biopharma compare to SCYNEXIS?

Summary

How does Aspire Biopharma compare to CervoMed?

Summary

How does Aspire Biopharma compare to Ayala Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aspire Biopharma (ASBP) Competitors

ASBP vs. GNTA, MIRA, SCYX, CRVO, and ADXS

How does Aspire Biopharma compare to Genenta Science?

Is GNTA or ASBP more profitable?

Do analysts rate GNTA or ASBP?

Do insiders & institutionals have more ownership in GNTA or ASBP?

Does the media prefer GNTA or ASBP?

Which has more risk & volatility, GNTA or ASBP?

Which has stronger valuation & earnings, GNTA or ASBP?

Summary

How does Aspire Biopharma compare to MIRA Pharmaceuticals?

Which has preferable valuation and earnings, MIRA or ASBP?

Is MIRA or ASBP more profitable?

Which has more volatility & risk, MIRA or ASBP?

Does the media refer more to MIRA or ASBP?

Do analysts rate MIRA or ASBP?

Do institutionals and insiders have more ownership in MIRA or ASBP?

Summary

How does Aspire Biopharma compare to SCYNEXIS?

Which has more risk and volatility, ASBP or SCYX?

Is ASBP or SCYX more profitable?

Does the media favor ASBP or SCYX?

Which has higher valuation & earnings, ASBP or SCYX?

Do institutionals and insiders believe in ASBP or SCYX?

Do analysts prefer ASBP or SCYX?

Summary

How does Aspire Biopharma compare to CervoMed?

Do analysts rate ASBP or CRVO?

Which has more risk & volatility, ASBP or CRVO?

Does the media favor ASBP or CRVO?

Is ASBP or CRVO more profitable?

Do insiders & institutionals have more ownership in ASBP or CRVO?

Which has better earnings and valuation, ASBP or CRVO?

Summary

How does Aspire Biopharma compare to Ayala Pharmaceuticals?

Do analysts rate ASBP or ADXS?

Is ASBP or ADXS more profitable?

Do insiders and institutionals hold more shares of ASBP or ADXS?

Which has stronger earnings and valuation, ASBP or ADXS?

Which has more volatility and risk, ASBP or ADXS?

Does the media favor ASBP or ADXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools